Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau
- PMID: 18043261
- DOI: 10.1097/CCO.0b013e3282f310de
Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau
Abstract
Purpose of review: To provide an overview of the recent advances in the understanding of the molecular mechanisms governing the tumour suppressor functions of the von Hippel-Lindau protein.
Recent findings: von Hippel-Lindau is a vital component of an E3 ubiquitin ligase complex involved in the oxygen-dependent targeting of hypoxia-inducible factor for ubiquitin-mediated destruction. Recent reports have linked von Hippel-Lindau to the regulation of diverse biological processes including cell adhesion, extracellular matrix assembly and ciliogenesis in a manner dependent and/or independent of hypoxia-inducible factor.
Summary: The tumour suppressor function of von Hippel-Lindau has remained hypoxia-inducible factor-centric since the discovery of von Hippel-Lindau as a bona fide negative regulator of the ubiquitous oxygen-sensing pathway. Emerging evidence supports this hypothesis with the elucidation of fundamental cellular processes deregulated upon the inactivation of the von Hippel-Lindau-hypoxia-inducible factor pathway, but has also proved compelling on the hypoxia-inducible factor-independent tumour suppressor role of von Hippel-Lindau. These and continuing studies into the molecular pathways and mechanisms governing the tumour suppressor functions of von Hippel-Lindau will ultimately afford new avenues for anticancer strategies for the improved treatment of a diverse array of cancers.
Similar articles
-
Von Hippel-Lindau syndrome: molecular mechanisms of the disease.Clin Transl Oncol. 2010 Mar;12(3):160-5. doi: 10.1007/s12094-010-0485-9. Clin Transl Oncol. 2010. PMID: 20231120 Review.
-
The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing.Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38. doi: 10.1016/j.bbrc.2005.08.165. Epub 2005 Aug 30. Biochem Biophys Res Commun. 2005. PMID: 16153592 Review.
-
Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.Am J Nephrol. 2004 Jan-Feb;24(1):1-13. doi: 10.1159/000075346. Epub 2003 Dec 3. Am J Nephrol. 2004. PMID: 14654728 Review.
-
Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.Cancer Res. 2006 Apr 1;66(7):3567-75. doi: 10.1158/0008-5472.CAN-05-2670. Cancer Res. 2006. PMID: 16585181
-
The von Hippel-Lindau tumor suppressor gene.Exp Cell Res. 2001 Mar 10;264(1):117-25. doi: 10.1006/excr.2000.5139. Exp Cell Res. 2001. PMID: 11237528 Review.
Cited by
-
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.Cancer Res. 2009 Dec 1;69(23):9056-64. doi: 10.1158/0008-5472.CAN-09-1770. Epub 2009 Nov 17. Cancer Res. 2009. PMID: 19920202 Free PMC article.
-
Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.Nat Med. 2011 Jun 19;17(7):845-53. doi: 10.1038/nm.2370. Nat Med. 2011. PMID: 21685897 Free PMC article.
-
Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction.Cancers (Basel). 2021 Feb 2;13(3):576. doi: 10.3390/cancers13030576. Cancers (Basel). 2021. PMID: 33540838 Free PMC article.
-
VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.J Biol Chem. 2009 Apr 17;284(16):10514-22. doi: 10.1074/jbc.M809056200. Epub 2009 Feb 19. J Biol Chem. 2009. PMID: 19228690 Free PMC article.
-
Regulation of endocytosis via the oxygen-sensing pathway.Nat Med. 2009 Mar;15(3):319-24. doi: 10.1038/nm.1922. Epub 2009 Mar 1. Nat Med. 2009. PMID: 19252501
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
